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Abstract
The grey matter of the brain contains high levels of the essential nutrient DHA. Although the role of DHA in the developing brain and in
dementia has attracted attention, its influence on the brain of the healthy adult has been little considered. A total of 285 young adult
females took 400 mg of DHA, in a double-blind, placebo-controlled trial, for 50 d. After 50 d, recently acquired information was more
likely to be forgotten by those who had consumed DHA. No significant differences in mood, reaction times, vigilance or visual acuity
were found.
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About 50–60 % of the dry weight of the brain is lipid, of which
35 % consists of PUFA(1). In fact, the nature of the dietary intake
of PUFA has neurophysiological consequences, as the nature of
the diet influences the composition of cell membranes and thus
the functioning of the brain(2). A review suggested that the
consumption of n-3 PUFA might beneficially affect neuronal
composition, neurotransmission and cognitive functioning.
Neurotransmission is influenced by two mechanisms: by
changing membrane fluidity and by increasing the release of
neurotransmitters(3). Epidemiological and developmental
research has suggested the role of n-3 PUFA in the regulation
of monoamine-mediated systems, cognition and affect: for
example, n-3 PUFA have been implicated in depressive
disorders, suicide, aggression and impulsivity(4,5).
Although low levels of DHA have been associated with
neurodegenerative diseases including dementia(6–8), the litera-
ture is limited and inconsistent. A prospective study(9) measured
the plasma fatty acid levels in older adults, but over a 3-year
period they were not associated with changes in cognition.
A cross-sectional longitudinal study(10) examined the relation-
ship between fish/n-3 consumption and cognitive performance
and after a 6-year follow-up found no association. However,
a 13-year prospective study of 3294 adults found that self-
reported cognitive difficulties were less frequent in those with
a higher consumption of n-3 PUFA, even after adjustment for
depressive symptoms. The authors concluded that cognitive
complaints were less frequent among the elderly who had a
high intake of n-3 PUFA 13 years earlier(11). Although some
observational studies have found that a better n-3 PUFA status
was beneficial, it is important that a 2-year double-blind, ran-
domised, controlled trial did not(12). Healthy older adults
(aged 70–79 years) took, each day, 200 mg EPA plus 500 mg
DHA, or olive oil, but there was no significant difference in cog-
nitive performance. The authors concluded that the relatively
short length of the intervention period might have masked the
potential beneficial effect of fish oil.
When considering the rate of cognitive decline, the time-
scale of supplementation may be critical. Benton(13) noted
that age-related changes in brain structure begin to occur up
to 60 years before they become overtly apparent as cognitive
problems. The time-scale of studies of older adults may have
in many instances failed to reflect the slow speed of the
processes they were trying to reduce. Yet it is known that
there is a rapid turnover of fatty acids in the brain, such that
over a relatively short period the structure of cell membranes
will reflect the diet of the recent past. In rats, Rapoport(14,15)
used radio-labelled PUFA to establish the rate at which they
were incorporated into brain phospholipids and found that
3–5 % of arachidonic acid (AA) and 2–8 % of DHA are lost
each day by metabolic mechanisms, to be potentially replaced
by dietary sources. Such a rate of turnover gave half-lives of
1–2 weeks for the exchange of AA and DHA between the
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plasma and brain. In human subjects, it was determined by
positron emission tomography that the human brain consumes
17·8 mg/d of AA and 4·6 mg/d of DHA; values that did not
change significantly with age(16). Thus, dietary supplementation
may increase the levels of plasma PUFA and in this way
influence the nature of their turnover in the brain and the result-
ing PUFA profile. It should, however, be remembered that there
are bodily compensations for a diet low in PUFA, so that there is
up-regulation of liver enzymes associated with the metabolism
of AA and DHA from their precursors(17).
Although there is a report in young adults that supplemen-
tation with DHA for 12 weeks was associated with increased cer-
ebral blood flow(17), cognition was not influenced and in fact
there has been little study on the influence of PUFA sup-
plements in this age group. Fontani et al.(18,19) reported that
n-3 supplements increased aspects of mood although never
was a significant difference with the placebo reported. Antypa
et al.(20) gave n-3 PUFA supplements for a month and measured
performance on a battery of tests and found few effects,
although the n-3 PUFA group made fewer risk-averse decisions.
In summary, a dietary increase of n-3 PUFA may influence
behaviour by changing the structure of cell membranes and
enhancing neurotransmission(2). To date, much of the research
has considered cognitive decline; however, as it takes place
over many years, it would not be expected to be susceptible
to a relatively short-term intervention. A possibility that has
been little considered is that there might be in young adults a
beneficial response to a relatively short-term intervention; one
that is long enough to reflect the rate of PUFA turnover. That
is, rather than looking to prevent cognitive decline, functioning
may be facilitated in the short-term by providing an optimal
intake for the healthy brain. The present study therefore gave
fatty acid supplements to young, healthy adults and monitored
cognition and mood.
Methods
For practical reasons, dictated by the ability to test a given
number of subjects, the study took place in two phases. Initially,
a group of 150 was recruited and subsequently a second group
of 150 subjects took part 3 months later. The data presented are
for these two parts combined. As it was possible that changes in
diet associated with the time of year might have influenced the
findings, initially the statistics allowed for any differences
between the two halves of the study to be distinguished. As
differences did not occur, they are not further mentioned. All
subjects took the battery of cognitive tests and then were ran-
domly allocated to either the DHA or placebo condition using
a double-blind procedure. Following baseline testing, four cap-
sules were taken each day. The cognitive battery was taken for a
second time after 25 d and for a third time after 50 d. The tests
were taken in the following order: mood, word list immediate
recall, reaction times, vigilance, word list delayed recall. In
addition, with the first half of the subjects, visual acuity was
measured after vigilance. With the second half of the subjects,
visual acuity was not measured but the recall of capital cities
was the first test of the battery, but only during the third testing
session (after 50 d). Trying to recall missing capitals on this
occasion was the final test of the sequence. The study was
conducted according to the guidelines of the Declaration
of Helsinki and all procedures were approved by the
ethics committee of the Psychology Department of Swansea
University. All subjects gave written informed consent.
Subjects
A total of 305 adult females, mean age 21·8 years and all univer-
sity students were recruited when they responded to a poster.
They gave written informed consent and were paid £30 for
taking part. The procedure was approved by the local ethics
committee. No subject was taking fish oil, or similar fatty acid
supplement, and all reported that they were in good health.
In total, 285 finished the trial although none reported withdraw-
ing because of side effects.
Supplements
Placebos and active capsules were produced by Martek Bio-
sciences Corporation. The active DHASCOw capsules contained
deodorised and bleached oil derived from the microalgae
Crypthecodinium cohnii, which was added to high-oleic sun-
flower oil so that 40 % of the resulting mixture was DHA. Anti-
oxidants, tocopherols (0·025 %) and ascorbyl palmitate
(0·025 %), and the flavouring ethyl vanillin with a sweet,
creamy, vanilla taste and odour, were added. The fatty acid pro-
file was as follows 10 : 0 (0·5 %); 12 : 0 (3·8 %); 14 : 0 (12·1 %);
16 : 0 (7·8 %); 18 : 0 (1·0 %); 18 : 1 (31·2 %); 18 : 2 (1·5 %); 22 : 0
(0·3 %); 22 : 6 (DHA) 40·1 %. Thus, there was no detectable
EPA or other long-chain PUFA. With this as composition, four
250 mg capsules a day offered 400 mg of DHA. The placebos
were identical in size, colour and smell to the active capsules
and contained maize/soya oil to which ethyl vanillin was
added. The fatty acid profile was as follows: 16 : 0 (11·0 %);
18 : 0 (3·0 %); 18 : 1 (23·3 %); 18 : 2 (56·7 %); 18 : 5 (4·1 %); 20 : 0
(0·4 %); 20 : 1 (0·3 %); 22 : 0 (0·2 %).
Cognitive tests
Recall of word list
For this test, three matched lists of thirty nouns were created,
all of five letters and one syllable in length. Nouns were selected
on the basis of high frequency (AA: .100/million words; A:
50–100/million words), high imagery and high concreteness(21).
They were presented at the rate of one word/s. Immediately
after presentation, the subjects wrote down as many words as
they could recall in 2 min (immediate memory task). Approxi-
mately 25 min later, following the other tests, the subjects
again tried to recall the words (delayed memory task). The
same word list was presented to all subjects at a particular test-
ing session.
Recall of capitals
This test was only given to the second group of subjects. As the
test could not be meaningfully repeated, it was administered
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only during the final testing session, that is after taking the cap-
sules for 50 d. In a pilot study, the subjects were asked to report
the capitals of various countries and, if they were unable to
recall them at that moment, to rate whether they thought they
knew them. From these responses, a list of thirty countries
was created, which consisted of countries where it was
common to report that they had a feeling that they knew the
capital although they were unable to recall the same.
The list of thirty countries was given to the subjects who, where
possible, mentioned the capital. Where they did not know the
answer, they rated their ‘feeling of knowing’ on a six-point
scale (1 ¼ very strong feeling of knowing to 6 ¼ definitely do
not know).
Having carried out the rest of the test battery, the list of
countries was given a second time and any capitals sub-
sequently remembered were reported. The responses obtained
on the second occasion were expressed as a portion of the
number of answers previously unanswered.
Reaction times
The reaction time procedure was based on that of Jensen(22). On
a panel, eight lamps were arranged in a semicircle 5·5 inches
from a central button (the home key). The index finger was
placed on the home key. Following a warning tone, one of
the eight lamps flashed and the subject pressed the button in
front of the illuminated lamp. The decision time is the time
taken to lift the finger from the home key. Simple and choice
decision times for each of two, four and eight lamps were
measured over twenty trials.
Rapid information processing task
A computer generated a series of digits at the rate of 100 digits/
min for 5 min. Subjects pressed the space bar when they
detected target sequences of three consecutive odd or three
consecutive even digits. In this manner, eight of these
sequences were presented every minute. The numbers of cor-
rect and incorrect responses were analysed.
Visual acuity
Visual acuity was measured using Snellen charts and was only
given to the first group of subjects. To increase sensitivity, the
charts were read from a distance of 5 m rather than the rec-
ommended 3 m. Thus two charts were presented, one of num-
bers and one of letters. Both charts were presented to the right,
and then both were presented to the left, eye. The measure ana-
lysed was the total number of letters and numbers that were not
reported correctly.
Mood assessment
Visual analogue scales (100 mm lines) were used to assess
how the subjects had felt ‘during the past week’: were they
energetic–tired, clearheaded–confused, composed–anxious,
confident–unsure, elated–depressed and agreeable–hostile?
These dimensions were derived from the factor analysis
that was carried out when the Profile of Mood States question-
naire(23) was developed.
Side effects
After taking the capsules, the subjects were asked if they had
experienced any side effects and also to indicate whether they
believed they were taking the active capsules, placebo or
could not tell.
Statistical analysis
Most analyses of the influence of DHA used a three-way
ANOVA; DHA/placebo £ first/second group of subjects £ time
(tested for the first, second or third time), with the last as a
repeated-measures factor. Significant interactions were
explored by the calculation of simple main effects. Whether
the results came from the first or second half of the subjects
did not influence the findings and these details are therefore
not reported. The effects of the capsules on the recall of capitals,
and ‘feeling of knowing’, were examined using t tests.
Results
Word list recall
When recall of the word lists was considered, the interaction
capsule £ time £ immediate/delayed recall (F(2,566) ¼ 4·41,
P,0·01) reached significance. Fig. 1 illustrates the interaction
that reflects differences between immediate and delayed
recall; that is the amount forgotten. Those taking DHA tended
to forget more at the end of the study. Post hoc tests found
that those taking DHA rather than the placebo forget more
after 50 d (P,0·01).
Placebo DHA
5
6
7
8
9
10
11
12
13
14
15
Baseline 25 d 50 d Baseline 25 d 50 d
Fig. 1. The influence of DHA supplementation on forgetting. The data are the
mean number of words forgotten between immediate ( ) and delayed ( )
recall of the word list. Those taking DHA forget more after 50 d (P,0·01).
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To consider whether this was a genuine effect, rather than
simply due to statistical chance, the sample was reanalysed in
two halves reflecting the first half of the subjects that had
been run as one group and the second half that was tested
some months later. In both cases, there was a trend for forget-
ting to be worse at the end of the study in those who took
DHA, albeit it did not reach statistical significance. The
number forgotten at the end of the study for the first group of
subjects was placebo 2·6 (SE 0·21) and DHA 3·2 (SE 0·28),
P,0·07, figures that compared well with the second half of
the study that produced values for the placebo of 2·6 (SE 0·27)
and DHA 3·2 (SE 0·29), P,0·09. There was evidence of a consist-
ent pattern that when these data were merged, it produced an
overall effect of 2·6 (SE 0·19) words being forgotten with the pla-
cebo and 3·2 (SE 0·19) with DHA (P,0·01).
Recall of capitals
Table 1 reports that those taking the DHA did not differ signifi-
cantly in terms of the number of capitals initially recalled, the
feeling that they knew the correct answer but were unable to
recall it, or the number of additional capitals recalled when
the task was undertaken for a second time.
Mood
The interaction capsule £ time failed to reach statistical signifi-
cance in the case of agreeable (F(2,566) ¼ 0·47, NS), clear-
headed (F(2,566) ¼ 0·02, NS), composed (F(2,566) ¼ 0·38,
NS), confident (F(2,566) ¼ 0·62, NS), elated (F(2,566) ¼ 0·19,
NS) and energetic (F(2,566) ¼ 1·57, NS). Mean values are pre-
sented in Table 1.
Table 1. The influence of DHA supplementation on mood and various measures of cognitive functioning*
(Mean values with their standard errors)
Baseline 25 d 50 d
Mean SE Mean SE Mean SE
Recall of capital cities
Initial recall
Placebo 14·0 5·8
DHA 12·5 5·2
Feeling of knowing
Placebo 5·0 0·56
DHA 5·0 0·52
Second recall
Placebo 1·4 0·15
DHA 1·4 0·15
Decision times
Placebo 353·7 4·4 353·2 3·5 353·2 3·4
DHA 346·9 4·4 342·4 3·6 346·1 3·4
Vigilance
Correct
Placebo 4·2 0·11 4·6 0·12 4·7 0·12
DHA 4·3 0·12 4·7 0·12 4·9 0·13
Incorrect
Placebo 2·6 0·86 2·1 0·24 2·1 0·36
DHA 4·0 0·89 2·7 0·25 2·4 0·37
Visual acuity
Placebo 20·5 1·8 19·4 1·8 18·9 1·9
DHA 20·2 1·8 19·2 1·8 19·1 1·9
Mood
Composed–anxious
Placebo 21·2 0·8 22·7 0·8 24·3 0·8
DHA 20·7 0·8 21·7 0·8 23·0 0·8
Agreeable–hostile
Placebo 26·2 0·7 26·0 0·8 27·1 0·7
DHA 25·5 0·7 25·7 0·8 26·3 0·7
Elated–depressed
Placebo 22·7 0·9 23·1 0·9 24·3 0·8
DHA 21·5 0·9 22·3 0·9 24·1 0·8
Confident–unsure
Placebo 20·4 0·8 21·4 0·8 22·7 0·8
DHA 19·5 0·8 20·1 0·8 21·9 0·8
Energetic–tired
Placebo 19·0 0·9 18·6 0·9 21·4 0·9
DHA 18·0 0·9 19·6 0·9 19·7 0·9
Clearheaded–confused
Placebo 22·1 0·8 22·6 0·8 24·4 0·8
DHA 21·2 0·8 22·4 0·8 23·5 0·8
* In no instance was there a significant difference between those taking the placebo and DHA.
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Visual acuity
The capsules did not influence visual acuity (capsule £ time –
F(2,286) ¼ 0·11, NS).
Reaction times
When the median decision times were examined, both the
capsule £ number of lamps £ time (F(6,1692) ¼ 0·45, NS)
and capsule £ day (F(2,564) ¼ 0·47, NS) interactions were
non-significant (Table 1).
Vigilance
Some subjects with this task used the strategy of continuously
pressing the bar so that by chance correct responses registered.
Therefore, any subject who had more than twenty errors in a
minute was removed from the analysis so that data are pre-
sented for 133 taking the placebo and 126 taking DHA. When
the number of sequences correctly identified was examined,
the capsule £ minutes of the session £ time interaction failed
to reach statistical significance (F(8,2056) ¼ 0·17, NS) and simi-
larly the capsule £ time interaction was non-significant
(F(2,514) ¼ 0·47, NS).
When the number of incorrect responses was examined,
neither the capsule £ minutes of the session £ time inter-
action (F(8,2056) ¼ 0·90, NS) nor the capsule £ time inter-
action (F(2,514) ¼ 0·52, NS) reached statistical significance.
Side effects
When asked after 50 d whether they had experienced any side
effects, 92 % of those taking the placebo and 95 % of those
taking the DHA, said no. Analysis using x 2 indicated that the
responses did not differ depending on which type of capsule
had been consumed. In the minority who reported side effects,
there was no systematic pattern. Physical and psychological
symptoms were equally likely to be reported and when
reported they were as likely to be positive as negative. Virtually
no symptom was mentioned more than once, but typical
examples included increased or decreased pre-menstrual symp-
toms, feeling less hungry, having more spots or poor finger-
nails, having improved memory and needing less sleep. When
asked to guess which treatment they had received, 60 % of
those taking the placebo said that they did not know, 8 % said
DHA and 32 % said placebo. Of those taking DHA, 65 % said
that they did not know, 19 % said DHA and 16 % said placebo:
responses that were not statistically different.
Discussion
The present study produced little evidence that DHA sup-
plementation influenced either cognition or mood. In fact, the
only significant finding was that DHA increased forgetting, an
unexpected finding (Fig. 1). That there was a trend for more
to be forgotten in both halves of the study supported the view
that it was a genuine rather than a chance result, but naturally
such a finding requires replication. The failure to find any
difference in the ability to recall the names of capitals (Table 1)
suggested that there was no problem in retrieving information
from long-term memory stores; and so the finding must reflect
some other aspect of the memory process. There is, however,
in principle, no reason why n-3 fatty acid supplementation
may not have both positive and negative influences.
The failure to find that mood was influenced is perhaps more
surprising (Table 1). Although methodological problems with
the studies have been noted, Fontani et al.(18,19) reported that
PUFA supplementation improved mood. Benton(24) considered
studies that had assessed aggression and in well-controlled trials
had given DHA supplements. In this connection, eight studies
were subjected to a meta-analysis that established a significant
beneficial effect of consuming DHA. As an example, Hamazaki
et al.(25) reported that 1·5–1·8 g of DHA/d for 3 months
decreased aggression towards others, in times of mental
stress. There is a parallel between these findings and those of
Iribarren et al.(26). In a study of risk factors associated with
heart disease in 3581 young adults, the consumption of any
fish rich in n-3 fatty acids, rather than no fish consumption,
was associated with a lower risk of hostility. In fact, there have
been suggestions that a tendency to consume a diet low in fat
predisposes to being aggressive. When monkeys ate a low-fat
diet (30 % rather than 43 % of energy from fat), they displayed
more aggression(27).
However, when for a month young adults ate a diet with
either 41 or 25 % of energy as fat, ratings of anger–hostility
were greater when less fat was consumed(28). However, for
3 months, Rogers et al.(29) gave EPA/DHA supplements to
individuals who were mildly to moderately depressed and
found no effect on measures of depression or on a range of
cognitive tests. They included their findings in a meta-analysis
and found that n-3 PUFA supplements offered negligible
benefits in terms of depressed mood. Interestingly, the effect
of the DHA supplement approached statistical significance
with a measure of impulsivity(29) (P,0·07), suggesting that
although mood in general may not be influenced, the possibility
that impulsivity and aggression are influenced should be further
considered. Antypa et al.(20), however, did not find an influence
on impulsivity although n-3 PUFA supplementation increased
risky decisions.
One possible explanation for the present study’s failure to
find an influence on mood is that the dose of DHA may be criti-
cal. The doses used in the eight studies reviewed by Benton(24)
varied but tended to offer at least 1·5 g DHA and in addition at
least 100 mg EPA, usually more. It is an obvious suggestion
that the dose in the present study was too low or that in addition
EPA should have been provided. An 85 g portion of salmon
offers about 1·2 g of n-3 fatty acids, which puts the dose in
perspective, although the recommendation to eat fish twice
a week is unlikely to provide the recommended intake of
1000–2000 mg/d.
Nevertheless, the failure to find a general effect on mood
agrees with work published since the present study was com-
pleted. Jackson et al.(30) gave one of three types of capsules
(450 mg DHA þ 90 mg EPA; 200 mg DHA þ 300 mg EPA; pla-
cebo) in healthy young adults aged 18–35 years. A battery of
cognitive tasks and measures of mood were completed before
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and after 12 weeks of supplementation. The authors described
the effects of both active treatments as minimal. The only signifi-
cant finding was that the high-EPA capsules reduced mental fati-
gue when under high cognitive demand. They concluded that
they had not produced solid evidence of any psychological
influence. Thus, it does not seem that the giving of EPA was
critical.
Jackson et al.(30) speculated that their negative findings might
have reflected the existing diet not providing a sufficiently low
level of n-3 fatty acids to allow a benefit from supplementation
to be observed. An animal study suggested that there might be a
threshold of n-3 PUFA intake below which there is a positive
response to supplementation. Jensen et al.(31) fed rats diets
that differed in their PUFA content. Only when brain levels of
n-3 PUFA fell to 22 % was the ability to perform in a water
maze compromised. Similarly, a South African study found a
response to fish oil in under-nourished but not well-nourished
children(32).
Jackson et al.(30) considered their finding that ratings of
mental fatigue were reduced in those consuming n-3 PUFA,
results similar to those of Antypa et al.(20) who also found
less fatigue in individuals taking fatty acids. They speculated
that the intake of EPA could modulate the metabolism of pro-
inflammatory AA-derived eicosanoids(33) and that a high level
of pro-inflammatory cytokines is associated with tiredness.
If so, a reduced AA:EPA ratio might be beneficial in times of
cognitive demand. The present findings that DHA supplemen-
tation did not decrease fatigue is consistent with this analysis
as the present supplement did not contain EPA, although until
the administration of DHA and EPA gets to be compared, this
remains only an interesting hypothesis.
The present findings, taken together with other recent nega-
tive reports, suggest that dietary supplementation with n-3
PUFA in healthy, impairment-free populations is unlikely to
result in cognitive enhancement. It should, however, be noted
that the lack of a measure of baseline fatty acid status or sub-
sequent changes is a weakness of the design that make the gen-
erality of the findings uncertain. However, the negative findings
are consistent with the few similar studies that have to date been
reported in adults(20,29,30) and children(34–37), although in chil-
dren there is an isolated partially positive report(32). It is there-
fore surprising that there is a widespread belief that the
consumption of n-3 fatty acids enhances the functioning of
the brain. A website selling n-3 supplements claimed thus:
‘Recent studies have shown that n-3 DHA and EPA can improve
learning, problem-solving skills, focus, memory and overall
brain function’ and recommended the consumption of their
product for those from 2 to 102 years of age. A list of the ten
best foods and supplements for brain health stated that: ‘A lack
of n-3 has been shown todiminish intellectual performance’. It is
important that individuals are not given false hopes, as although
to date there have been few studies on this topic, the findings
are consistently negative.
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